Protection against HPV-16-Associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells

Molecular Cancer Therapeutics

Volumn 15, Issue 8, 2016, Pages 1920-1930

  Diniz, Mariana O ^a   Sales, Natiely S ^a   Silva, Jamile R ^a   Ferreira, Luís Carlos S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL ANTIBODY; DNA VACCINE; GLYCOPROTEIN D E7 ONCOPROTEIN VACCINE; INTERLEUKIN 2; ONCOPROTEIN; UNCLASSIFIED DRUG; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECHALLENGE; EFFECTOR CELL; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; COMPLICATION; DISEASE MODEL; DRUG SCREENING; HUMAN; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASMS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; VIROLOGY;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TUMOR BURDEN; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84986287970     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0742     Document Type: Article

References (50)

1. Turtle CJ, Riddell SR. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 2011;23:299-305.
2. Melief CJ.Cancer immunotherapy by dendritic cells. Immunity 2008;29: 372-83.
3. Gajewski TF.Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61.
4. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-83.
5. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175:6169-76.
6. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008;68:2993-3000.
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
8. Young MR, Petruzzelli GJ, Kolesiak K, Achille N, Lathers DM, Gabrilovich DI. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. Hum Immunol 2001;62: 332-41.
9. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
10. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30.
11. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013;62:1711-22.
12. Rudolph BM, Loquai C, Gerwe A, Bacher N, Steinbrink K, Grabbe S, et al. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol 2014;23:202-4.
13. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGFbeta1. J Immunol 2009;182:240-9.
14. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001;24: 431-46.
15. Gabrilovich D.Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
16. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloidderived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174: 636-45.
17. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
18. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;3124:S3/11-25.
19. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009;9:347-56.
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
21. Diniz MO, Cariri FAOM, Aps LRMM, Ferreira LCS. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Hum Gene Ther 2013;24:861-70.
22. Lin KY, Guarnieri FG, Staveley-O'Carrol KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
23. Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Antitumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect 2005;7:1541-50.
24. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012;7:e40677.
25. Callahan MK, Wolchok JD. At the Bedside: CTLA-4 and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013;94:41-53.
26. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
27. Atkins MB.Interleukin-2: clinical applications. Semin Oncol 2002;29: 12-7.
28. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 2006;107: 2409-14.
29. Mahmud SA, Manlove LS, Farrar MA. Interleukin-2 and STAT5 in regulatory T cell development and function. JAKSTAT 2013;2:e23154.
30. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006;441:890-3.
31. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010;32:79-90.
32. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001;61:5850-6.
33. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, et al. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 2003;63:5601-6.
34. Durrant LG, Pudney V, Spendlove I, Metheringham RL. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. Expert Opin Biol Ther 2010;10:735-48.
35. Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity antitumor CD8+ T cells. Eur J Immunol 2006;40: 899-910.
36. Cho JH, Youn JW, Sung YC. Cross-priming as a predominant mechanism for inducing CD8 T cell responses in gene gun DNA immunization. J Immunol 2001;167:5549-57.
37. Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, et al. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 2010;28:5794-802.
38. Kang TH, Knoff J, Yeh WH, Yang B, Wang C, Kim YS, et al. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8+ T cell-mediated antitumor effects PLoS One 2014;9: e103562.
39. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008;180: 6649-55.
40. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol 2013;13:227-42.
41. Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, Rux JJ, et al. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 2008;14:205-12.
42. Sciortino MT, Medici MA, Marino-Merlo F, Zaccaria D, Giuffrè-Cuculletto M, Venuti A, et al. Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D. Cell Microbiol 2008;10:2297-311.
43. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
44. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
45. Huster KM, Stemberger C, Busch DH. Protective immunity towards intracellular pathogens. Curr Opin Immunol 2006;18:458-64.
46. van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber WJ, et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol 2012;189: 3397-403.
47. Kang TH, Knoff J, Yeh WH, Yang B, Wang C, Kim YS, et al. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8+ T cell-mediated antitumor effects. PLoS One 2014;29: e103562.
48. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008;15: 5791-802.
49. Wilcox RA.Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc 2010;85:656-63.
50. Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, Gruijl TD. Crosstalk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011;3:77-96.